Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

Share Price is delayed by 15 minutes
Get Live Data
2170.00    60.00 (2.84%)
Bid:
2180.00
Ask:
2186.00
Spread: 6.00 (0.275%)
Market Cap: £1.44b
GNS Live PriceLast checked at - London Stock Exchange

Intraday Genus Share Chart

Board Appointment

7 May 2009 07:00

RNS Number : 8018R
Genus PLC
07 May 2009
 



For immediate release 7 May 2009

Genus plc

('Genus' or 'the Company')

Board Appointment

Genus, a leading global animal genetics company, is pleased to announce the appointment of Mike Buzzacott as a non-executive director.

Mike Buzzacott spent 34 years at BP prior to his retirement in 2004, holding a number of international roles including Finance & Control Director Asia Pacific, CFO BP Nutrition and Group Vice President Petrochemicals. He is currently a non-executive director and Audit Committee chairman of Rexam Plc (retiring in May 2009) and Croda Plc. He is also a non-executive director of Scapa Plc. He was Chairman of Biofuels Plc from 2006 until its re-registration in 2007 as a private company.

Mike Buzzacott will chair the Company's Audit Committee and will be a member of the Remuneration Committee.

Commenting on the appointment, John Hawkins, Chairman of Genus, said:

"We are delighted to welcome Mike to the Board. He brings with him considerable experience gained in overseas international markets that will greatly benefit Genus during its next stage of strategic development and beyond."

There are no further details to be disclosed in respect of Mike Buzzacott under paragraph 9.6.13R of the Listing Rules of the UK Financial Services Authority.

For further information please contact:

Genus plc Tel: 01256 345970

John Hawkins, Chairman

Richard Wood, Chief Executive

Buchanan Communications Tel: 0207 466 5000

Charles Ryland , Isabel Podda

About Genus

Genus creates advances to animal breeding through biotechnology and sells added value products for livestock farming and food producers. It's non-Genetically Modified Organism (GMO) technology is applicable across all livestock species but is only commercialised by Genus in the bovine and porcine farming sectors.

Genus' worldwide sales are made in seventy countries under the trademarks "ABS" (dairy and beef cattle) and "PIC" (pigs) and comprise semen and breeding animals with superior genetics to those animals currently in production. Customers' animals produce offspring with greater production efficiency, milk and meat output and quality and use these to supply the global dairy and meat supply chain. 

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and the Group's global production and distribution network.

Headquartered in BasingstokeEngland, Genus companies operate in 30 countries on six continents, with research laboratories located in MadisonUSA.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOACKAKDPBKDDPK
Date   Source Headline
3rd Oct 20132:00 pmRNSAdditional Listing
2nd Oct 20135:00 pmRNSTotal Voting Rights
27th Sep 20136:19 pmRNSDirector/PDMR Shareholding
23rd Sep 20137:00 amRNSGenus to Acquire Génétiporc
3rd Sep 20133:04 pmRNSCorrection of Record Date
3rd Sep 20137:00 amRNSPreliminary Results
31st Jul 20133:00 pmRNSBlocklisting Interim Review
25th Jul 201310:14 amRNSCompany Secretary Appointment
18th Jul 20139:00 amRNSHolding(s) in Company
11th Jun 20135:07 pmRNSHolding(s) in Company
4th Jun 20139:10 amRNSHolding(s) in Company
31st May 20132:00 pmRNSTotal Voting Rights
23rd May 20138:22 amRNSDirector/PDMR Shareholding
21st May 20134:56 pmRNSHolding(s) in Company
30th Apr 20137:00 amRNSInterim Management Statement
8th Apr 20136:09 pmRNSHolding(s) in Company
8th Apr 201310:27 amRNSHolding(s) in Company
28th Mar 20134:13 pmRNSHolding(s) in Company
28th Mar 20133:51 pmRNSTotal Voting Rights
21st Mar 20132:00 pmRNSHolding(s) in Company
11th Mar 20134:07 pmRNSDirector/PDMR Shareholding
4th Mar 20132:00 pmRNSHolding(s) in Company
28th Feb 20132:30 pmRNSTotal Voting Rights
28th Feb 20132:00 pmRNSDirector/PDMR Shareholding
25th Feb 20134:21 pmRNSDirector/PDMR Shareholding
25th Feb 20137:00 amRNSInterim Results
25th Feb 20137:00 amRNSSecond New Joint Venture in China
4th Feb 201310:00 amRNSHolding(s) in Company
31st Jan 20132:00 pmRNSBlocklisting Interim Review
31st Jan 20132:00 pmRNSTotal Voting Rights
8th Jan 20132:00 pmRNSHolding(s) in Company
13th Dec 20127:00 amRNSDirectorate Change
7th Dec 201210:00 amRNSDirector/PDMR Shareholding
30th Nov 20122:00 pmRNSTotal Voting Rights
14th Nov 201210:00 amRNSHolding(s) in Company
8th Nov 20123:30 pmRNSAGM Statement
8th Nov 20127:00 amRNSAGM and Interim Management Statement
31st Oct 20122:03 pmRNSTotal Voting Rights
26th Oct 201210:00 amRNSHolding(s) in Company
17th Oct 201210:00 amRNSHolding(s) in Company
9th Oct 20122:00 pmRNSAnnual Report and details of AGM
28th Sep 20122:00 pmRNSTotal Voting Rights
27th Sep 201211:00 amRNSAdditional Listing
27th Sep 20128:00 amRNSHolding(s) in Company
26th Sep 20124:01 pmRNSDirector/PDMR Shareholding
4th Sep 20127:00 amRNSPreliminary Results
31st Aug 20122:00 pmRNSTotal Voting Rights
23rd Aug 20126:18 pmRNSHolding(s) in Company
20th Aug 20127:00 amRNSAppointment of Joint Broker
31st Jul 20122:00 pmRNSBlocklisting Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.